#United States #New York #Class Action #Investor Rights #Regeneron Pharmaceuticals

Class Action Lawsuit Filed Against Regeneron Pharmaceuticals, Inc.

On February 6, 2025, the Gross Law Firm made a significant announcement regarding a class action lawsuit against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). This lawsuit aims to hold Regeneron accountable for alleged misleading practices that have impacted investors who purchased shares during a specified time period. The law firm has called upon shareholders who acquired shares between November 2, 2023, and October 30, 2024, to come forward and participate in the lawsuit.

Allegations Against Regeneron Pharmaceuticals

The primary allegations in this lawsuit assert that Regeneron made materially false and misleading statements, alongside a lack of disclosure regarding crucial financial practices. Key points highlighted in the complaint include:

1. Payment of Credit Card Fees: It is alleged that Regeneron paid credit card fees to distributors, contingent upon them not charging customers more when using credit cards for one of its flagship products, Eylea.
2. Price Concessions: These payments reportedly subsidized customer prices when purchasing Eylea with credit cards. Consequently, Regeneron positioned itself advantageously by lowering the selling price of Eylea without transparent communication.
3. Competitive Advantage: Due to retinal practices being price-sensitive, Regeneron's concessions on prices provided an unfair competitive edge in the anti-VEGF medication market.
4. Misleading Sales Reporting: The lawsuit posits that Regeneron's actions misleadingly inflated reported sales of Eylea, which directly misrepresented the drug's market performance.
5. Overstated Average Selling Price (ASP): The failure to report payment of credit card fees as price concessions supposedly resulted in an overstated ASP reported to federal agencies, constituting a violation of the False Claims Act.
6. Misleading Statements: Overall, the defendants' public statements regarding Regeneron's business performance and outlook are claimed to be materially misleading and lacking a reasonable basis.

Participation Details for Shareholders

The deadline for shareholders looking to participate as lead plaintiffs in this class action is March 10, 2025. Interested individuals are encouraged to register via the Gross Law Firm's website, where they can gain access to portfolio monitoring software that will provide updates throughout the case's progression. Importantly, there is no cost or obligation tied to participating in this lawsuit.

Why the Gross Law Firm?

Known nationally for handling class action cases, the Gross Law Firm is dedicated to safeguarding investor rights against deceitful, fraudulent, and unlawful business practices. Their mission is to ensure that companies adhere to ethical business conduct and that investors can seek recovery for losses attributed to misleading corporate behavior.

Contact Information

For shareholders or interested parties seeking more information, the Gross Law Firm can be contacted via:

• - Phone: (646) 453-8903
• - Email: [email protected]
• - Address: 15 West 38th Street, 12th Floor, New York, NY 10018

As this case develops, it could serve as a critical moment for investors demanding transparency and accountability from Regeneron Pharmaceuticals. Shareholders who feel they have been misled are urged to act swiftly to ensure their inclusion in the class action.

• ---

Failure to participate may result in the loss of vital rights related to this legal matter, reinforcing the importance of staying informed and proactive.